LLY Stock Recent News
LLY LATEST HEADLINES
Eli Lilly (LLY 3.47%) has a strong pipeline of new medicines that could increase the stock price.
Eli Lilly (LLY 3.47%) is gaining market share in a lucrative market that could be a catalyst for a stock price increase.
The company delivered 45% revenue growth in Q1 2025, driven by ZEPBOUND and MOUNJARO's strong performance in the obesity and diabetes markets. ZEPBOUND outperformed Novo Nordisk's WEGOVY in terms of weight loss, solidifying Lilly's leadership in the booming global anti-obesity drug market space. The company's oral GLP-1 agonist orforglipron showed promising phase 3 results, positioning the company ahead of competitors in T2D and possibly the obesity drug treatment space.
The global weight-loss drug market, once dominated by Novo Nordisk, is undergoing a dramatic transformation. On Friday, the Danish pharmaceutical giant announced it would replace its long-serving chief executive, Lars Fruergaard Jorgensen, as the company faces mounting pressure from rivals and a sharp slide in its stock value.
Evan David Seigerman, BMO Capital Markets head of healthcare research, joins CNBC's 'Money Movers' to discuss reactions to the departure of Novo Nordisk's CEO, what is means for the company's trajectory, and more.
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Eli Lilly and Company (NYSE:LLY ) BofA Securities 2025 Health Care Conference Call May 15, 2025 11:40 AM ET Company Participants Lucas Montarce - CFO Mike Czapar - SVP, IR Conference Call Participants Tim Anderson - Bank of America Tim Anderson Thanks for joining us. I'm Tim Anderson, the U.S. Pharma and Biotech analyst at Bank of America.
President Donald Trump's first 100 days in office occurred between Monday, Jan. 20, and Tuesday, April 29. During this period, the S&P 500 (^GSPC 0.10%) and Nasdaq Composite (^IXIC 0.72%) dropped by 7% and 11%, respectively.
Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid growth prospects.
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Eli Lilly (LLY). But which of these two companies is the best option for those looking for undervalued stocks?